Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | LIPE | Q05469 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26676803 | 0.80 | LIPE (0.43) | MAPTLIPEGAAALDH1A1LMNA | |
| SCHEMBL25322253 | 0.74 | POLB (0.41) | MAPTLIPEALDH1A1LMNA | |
| SCHEMBL4304347 | 0.74 | ALDH1A1 (0.33) | MAPTLIPEALDH1A1LMNA | |
| SCHEMBL25323532 | 0.74 | ALDH1A1 (0.33) | MAPTLIPEALDH1A1LMNA | |
| SCHEMBL9895421 | 0.74 | POLB (0.41) | MAPTLIPEALDH1A1LMNA | |
| SCHEMBL17892791 | 0.74 | POLB (0.41) | MAPTLIPEALDH1A1LMNA | |
| SCHEMBL24365183 | 0.74 | CHRM2 (0.44) | — | |
| SCHEMBL9895236 | 0.72 | MAPT (0.31) | MAPTLIPE | |
| SCHEMBL9900151 | 0.72 | KDM4E (0.33) | MAPTLIPEALDH1A1LMNA | |
| SCHEMBL9898712 | 0.71 | THRB (0.33) | ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10906888-B2 | Pyrimidine carboxamides as inhibitors of Vanin-1 enzyme | PFIZER INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-20190315715-A1 | NOVEL PYRIMIDINE CARBOXAMIDES AS INHIBITORS OF VANIN-1 ENZYME | PFIZER INC. (US) | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315715-A1 | NOVEL PYRIMIDINE CARBOXAMIDES AS INHIBITORS OF VANIN-1 ENZYME | VNN1, DPYD, MVD | MAPT 4493/4885LIPE 1717/4885GAA 54/4885 |
| US-10906888-B2 | Pyrimidine carboxamides as inhibitors of Vanin-1 enzyme | VNN1, DPYD, MVD | MAPT 4540/4885LIPE 1373/4885GAA 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.